US 12,616,725 B2 · Bifidobacterium breve IDCC 4401 strain and its dead cell ID-BBR4401 having excellent acid tolerance and bile tolerance and prophylactic or therapeutic effect on dyslipidemia

Abstract

The present invention relates to a novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) and dead cell thereof ID-BBR4401, which are superb in acid tolerance and bile tolerance and have a preventive or therapeutic effect on dyslipidemia. Having not only an excellent effect of reducing a cholesterol level in the body but alto a very high level of acid tolerance and bile tolerance in contrast to previously known B. breve, the novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) of the present invention well exhibits the functionality that the strain has in the digestive duct of animals (especially humans), has an excellent growth potential, and provides sustainable and effective functionality of reducing a level of cholesterol in vivo.

Claims1

Dependent claims

A method of treating dyslipidemia comprising administering to a mammalian subject in need thereof a composition comprising an effective amount of at least one of the isolated Bifidobacterium breve IDCC 4401 strain having the accession number KCTC13169BP, a culture thereof, or a heat-treated dead cell of the isolated Bifidobacterium breve IDCC 4401 strain.

Dependencies are inferred from the claim text.

Facts

Application

18/148,955Filed 30 Dec 2022 · continuation

Priority

KR 10-2020-008058830 Jun 2020

Published

US 2023/0285474 A114 Sep 2023

Granted

5 May 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 35/745
Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs: bifidobacteria
A23K 10/16
Obtained by microbiological or biochemical processes: addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff…
A23K 10/18
Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions: of live microorganisms
A23L 33/135
Using additives: bacteria or derivatives thereof, e.g. probiotics

Bifidobacterium breve IDCC 4401 strain and its dead cell ID-BBR4401 having excellent acid tolerance and bile tolerance and prophylactic or therapeutic effect on dyslipidemia

Life of this patent

Bifidobacterium breve IDCC 4401 strain and its dead cell ID-BBR4401 having excellent acid tolerance and bile tolerance and prophylactic or therapeutic effect on dyslipidemia

Life of this patent

Abstract

Claims1